Clinical Trial Update: Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis [Phase 3]

View source ↗

Summary

Phase 3 trial comparing ofatumumab to teriflunomide in relapsing multiple sclerosis completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing Multiple Sclerosis

Drugs mentioned

• Ofatumumab (ofatumumab)
• Teriflunomide (teriflunomide)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Relapsing Multiple Sclerosis | Phase 3 | Status: COMPLETED | Results posted: 2020-10-19